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BACKGROUND: Non-compliance with oral treatment in oncology is an emerging health issue. For breast cancer (BC) patients, few data
are available on compliance and persistence to tamoxifen in younger women and to aromatase inhibitors (AIs) as compared with
tamoxifen in older women.
METHODS: We constituted a cohort of 13479 women with BC who received at least one prescription of tamoxifen or AI between
1998 and 2008, in the United Kingdom General Practice Research Database. Days covered by medication and treatment
discontinuation were studied. Time to treatment discontinuation was calculated using Kaplan–Meier estimates.
RESULTS: Overall, 18.9% (95% CI: 15.1–23.0) of women on AIs as compared with 31.0% (95% CI: 29.6–32.2) of women on tamoxifen
had discontinued their treatments within the first 5 years (Po0.001). This rate raised to 50.7% (95% CI: 43.0–57.9) among the 416
women under 40 years receiving tamoxifen as initial hormonal therapy. Among older women, treatment discontinuation was less
frequent for AIs as compared with tamoxifen (Po0.001). Among women on AI therapy, 14% of them (n¼374) had switched
treatments.
CONCLUSION: Among older women, the real-life patterns of use of AI show high rates of compliance. In younger women, tamoxifen is
prematurely discontinued for half of patients.
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In the field of oncology, the use of oral therapy is increasing and
treatment compliance issues are of growing interest (Partridge
et al, 2002; Ruddy et al, 2009). Oral adjuvant hormonal therapy in
hormonal-responsive early breast cancer (BC) reduces the risk of
recurrence and increases survival rates (Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG), 2005). For the last
20 years, a 5-year tamoxifen treatment was the standard therapy
for all women diagnosed with hormone-sensitive BC. More
recently, aromatase inhibitors (AIs) were shown to further reduce
the risk of recurrence or death from BC as compared with
tamoxifen in post-menopausal women (Crivellari et al, 2008;
Forbes et al, 2008) and constitute an alternative option now
recommended for the adjuvant treatment of early BC (National
Institute for Health and Clinical Excellence, 2006; Goldhirsch et al,
2009; Burstein et al, 2010).
Non-compliance and early discontinuation of hormonal treat-
ments are likely to affect treatment efficacy in BC patients (Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005;
McCowan et al, 2008; Dezentje et al, 2009). In previously published
observational studies, depending on the methodology used,
discontinuation rates for tamoxifen ranged from 17% at 2 years
to 49% at 5 years (Demissie et al, 2001; Partridge et al, 2003;
Fink et al, 2004; Lash et al, 2006; Barron et al, 2007; Kahn et al,
2007; Owusu et al, 2008; Ziller et al, 2009; Hershman et al, 2010)
and from 21 to 51% at a 3-year maximal follow-up for AIs
(Partridge et al, 2008; Ziller et al, 2009; Hershman et al, 2010).
Comparison of non-persistence between tamoxifen and AIs is
difficult as the majority of past studies have often used different
methodologies rendering external comparison inappropriate.
Tamoxifen and AIs present different side-effect profiles that may
in turn affect the patient’s compliance with the treatment
differently outside controlled clinical trials. Specific functional
side effects of AIs such as arthralgia, observed in routine check-
ups, are likely to further reduce compliance. The superiority of the
efficacy of AIs over tamoxifen observed in clinical trials, where
compliance is likely to be optimal (Osterberg and Blaschke, 2005),
may be diminished in real life owing to differential non-
compliance rates. Studying further the difference in compliance
between tamoxifen and AIs is therefore crucial.
Few data are available on compliance with and persistence to
tamoxifen in younger women. Indeed, most studies focused on
older women and excluded premenopausal women. Only four
studies included women with a large age range (Partridge et al,
2003; Barron et al, 2007; Kahn et al, 2007; Hershman et al, 2010).
These four studies found younger age to be associated with lower
compliance or higher discontinuation rates. However, they did not
provide detailed data for this age group and relied on self-reports
of compliance or on databases covering specific subsamples of the
general population. Therefore to date, no study on younger women
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shas provided detailed data on tamoxifen use in a population-
based setting.
Our objective was therefore to study patterns of use of tamoxifen
and AIs in an observational population-based cohort of women
with BC. We secondly focused on two specific aspects: first,
tamoxifen use in younger women with BC; second, AI use as
compared with tamoxifen use in older women.
METHODS
Source of data
The United Kingdom (UK) General Practice Research Database
(GPRD) constituted the primary source of data. It comprises data
on over 4.4 million currently active individuals (approximately 7%
of the English population) collected prospectively from 1987 to
present. Data collected to date comprise over 55 million person
years of research quality data. As the UK National Health Service
provides universal coverage, the database is population based, all
segments of the population being represented. The medical
practices participating in the GPRD show a geographic distribution
representative of the UK population. Age and sex distributions of
patients in the GPRD reflect those reported by the National
Population Census (Garcia Rodriguez et al, 2002).
In the UK, GPs are the primary care givers for all patients in the
National Health Service and therefore all consultants are required
to inform the referring GP on clinical events and medical
diagnoses whenever a patient is seen in hospital or by an
outpatient specialist.
The database records a large amount of medical information
including comprehensive records of prescriptions written, all
clinically medical diagnoses both in-patient and outpatient, and
referrals to hospitals. Prescriptions supplied by GPRD physicians
are automatically recorded in the database. The recorded
information on drug exposures and diagnoses has been validated
(Lawrenson et al, 1999, 2000; Jick et al, 2003). More specifically,
the GPRD has been shown to provide BC incidence closely similar
to the national registration data (Kaye et al, 2000).
The study protocol was approved by the Scientific and Ethical
Advisory Group of the GPRD.
Study population
Cohort definition. We constituted a cohort of women diagnosed
with BC and who received at least one prescription of tamoxifen,
anastrozole, letrozole, or exemestane between 1 January 1998 and
30 June 2008. Breast cancer was identified using a code for breast
surgery combined with a diagnostic code of invasive cancer. All
diagnoses were identified using a list of codes for diagnosis and
procedures available in the GPRD relying on the READ classifica-
tion. Medications from the recorded prescriptions are identified
using the coded drug dictionary based on the UK Prescription
Pricing Authority Dictionary.
Cohort entry was defined as the date of first prescription of
tamoxifen/AI. The maximum delay between the diagnostic code
and the first prescription was 1 year to increase the likelihood that
the treatment was prescribed as an adjuvant treatment for primary
BC. We excluded patients who had a previous history of BC. We
also excluded women who were metastatic at diagnosis or within
the first 6 months after diagnosis. Patients who were prescribed
simultaneously tamoxifen and AI and patients who had less than a
year of data before cohort entry were also excluded.
All patients were followed from cohort entry to the end of
treatment (theoretically 5 years), or until death from any cause, BC
recurrence or contralateral BC, thrombo-embolic event, or
endometrial cancer, whichever came first. If a patient switched
between tamoxifen and AI or between two AIs during the study
period, follow-up was censored at the time of the switch to
calculate the compliance and persistence to the first drug.
Subcohorts were constituted according to age and date of
diagnosis to account for the changes over time in clinical
guidelines. Compliance and persistence were studied separately
for women under 40 years of age and women 50 years and over at
the time of diagnosis. For the younger group, tamoxifen was the
only treatment studied as it remains the main therapeutic option
for hormonal treatment in this mostly pre-menopausal subgroup
of patients (Tam 40). For the latter group, owing to the recent
recommendations on the use of AIs as adjuvant hormonal
treatment in post-menopausal patients, these women were
stratified according to the date of diagnosis to create an historical
comparison group of tamoxifen users. This reference group was
defined as having a diagnostic date before 2000 (Tam 50), when
tamoxifen was generally prescribed for a 5-year period. Compli-
ance and persistence to medication in this reference group was
compared with the compliance and persistence to AIs among
women diagnosed after 2006 (AI 50). Indeed, anastrozole and
letrozole were licensed as adjuvant treatments for early BC in post-
menopausal women in 2004 and 2005, respectively, in the UK, and
UK clinical guidelines were updated in 2006 (National Institute for
Health and Clinical Excellence, 2006).
Definition of measures of medication compliance and persistence.
Compliance was defined as the numbers of days covered by
medication divided by the number of days between cohort entry and
end of study participation. This proportion corresponds to the
medication possession ratio (MPR) (Andrade et al, 2006; Cramer
et al, 2008). For each woman, number of days covered by
medication was calculated from the number of tablets prescribed
combined with dosing instruction. From this information, we
calculated the duration of the prescription. Durations of overlapping
prescriptions were not added. A conventional cutoff of 80% or more
days covered was used to calculate the proportion of women who
where compliant with treatment (Fisher et al, 1989; Love, 1990;
Waterhouse et al, 1993; Partridge et al, 2008). Women whose MPR
was less than 80% were considered as non-compliant. We studied
non-persistence to treatment defined as the first treatment
discontinuation longer than 3 months. A gap of 3 months or more
in medication coverage identified treatment discontinuation.
All treatments were handled similarly to limit differential
misclassification of exposure.
Statistical analysis
Descriptive statistics were computed for continuous data (mean±
standard deviation (s.d.)) and categorical data (sample size and
percentage). Time to treatment discontinuation was calculated
using Kaplan–Meier estimates to account for censored data.
Patients follow-up was censored at 5 years (the theoretical
duration of treatment), or at the date of death, BC recurrence or
contralateral BC, thrombo-embolic event, endometrial cancer, or
switch to a different antihormonal treatment, whichever came first.
Results are expressed as cumulative probabilities of treatment
discontinuation with 95% confidence intervals (CIs). Kaplan–
Meier estimates of treatment discontinuation of the different
subgroups were compared using the log-rank test.
All analyses were conducted with SAS version 9.1 (SAS Institute,
Cary, NC, USA).
RESULTS
In the GPRD, we identified 24489 women who received a first
prescription of tamoxifen, anastrozole, letrozole or exemestane
after 1 January 1998, who also had at least 1 year of data before this
prescription in the database. We excluded 4218 women owing to
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sthe absence of a BC diagnostic code in their records, 5517 women
because BC was diagnosed before the study period, 397 women
because of metastases before or within the first 6 months after
diagnosis and 17 had no date of diagnosis. We further excluded
516 women who received their first prescription more than
3 months before BC diagnosis, 328 who received their treatment
more than a year after diagnosis and 17 women who were
prescribed two drugs concomitantly (Figure 1). We therefore
constituted a cohort of 13479 women who received tamoxifen
(n¼10806) or one of the AIs (n¼2673) following the diagnosis of
BC. Mean age at cohort entry was 62 years (s.d.¼14.0) in the
tamoxifen group and 70.8 (s.d.¼12.4) in the AI group (Table 1).
We identified 416 women under 40 receiving tamoxifen as initial
hormonal therapy (Tam 40), 1435 women over 50 diagnosed with
BC before 2000 and receiving tamoxifen (Tam 50) and 1562 women
over 50 diagnosed after 2006 and receiving AI (AI 50).
In the entire cohort, treatment discontinuation reached 29.8% of
patients at 5 years. This rate ranged from 18.9% (95% CI: 15.1–
23.0) for AIs users to 31.0% (95% CI: 29.6–32.2) for tamoxifen
users (Po0.001) (Figure 2).
In the three subcohorts, rates of the treatment discontinuation
in the first year ranged from 5.2% (95% CI: 4.0–6.6) to 20.1% (95%
CI: 16.2–24.2) in the AI 50 and in the Tam 40 groups, respectively
(Figure 3). At 5 years, more than half of the women (50.7%; 95%
CI: 43.0–57.9) in the Tam 40 group had discontinued their
treatment. Among women over 50, treatment discontinuation was
less frequent for AIs as compared with tamoxifen (Po0.001).
Table 2 describes non-compliance, that is, MPR lower than 80%
for patients receiving at least one prescription within that year. In
the first year of treatment, non-compliance ranged from 9.5% in
the AI 50 group to 23.6% in the Tam 40 group. Non-compliance
reached 51.8% at 5 years in the latter group.
In the AI 50 group, 9.6% of women (150 out of 1562) had switched
treatment by June 2008, corresponding to last data available for our
study. Half of them switched from one AI to another AI, and the other
half switched from AI to tamoxifen. Switches occurred within the first
year of treatment in 76% of cases. Among women over 50 years of age
who started a tamoxifen therapy after 2000, 31% switched to AI over
t h ec o u r s eo ft h es t u d y .O ft h e s ew omen, 12% switched within the
first year of treatment (11.1 and 13.7% for women diagnosed in
2000–2004 and after 2005, respectively). A switch within the first year
indicates a change in treatment not in accordance with medical
guidelines, which recommend continuing tamoxifen treatment for a
minimum of 2–3 years. This may indicate a switch for other reasons
such as side effects.
DISCUSSION
Among older women, the real-life patterns of use of AI show high
rates of persistence to treatment. As compared with tamoxifen,
AI therapy appears to be less frequently discontinued. In younger
women, tamoxifen is prematurely interrupted for half of patients.
In clinical trials, compliance is likely to be optimal owing to the
close monitoring of patients and the volunteer nature of such
studies (Osterberg and Blaschke, 2005). Indeed, in the three largest
trials on adjuvant tamoxifen for BC, about 20% of women
discontinued their treatment prematurely (2001). In the ATAC
trial, 88% of women allocated to AIs as compared with 87% on
tamoxifen reported to be compliant with their treatment at 5 years
(Forbes et al, 2008). Compliance rates in observational studies
such as ours are expected to be lower than those reported in trials,
and indeed our results are closer to those of previously published
observational studies. Partridge et al (2008) reported for the first
Women with at least one prescription
of tamoxifen/aromatase inhibitors
after 1 January 1998, with at least 
one year of data before
this prescription
(n=24489)
- Absence of a breast cancer
diagnostic code (n=4218)
- Presence of a breast cancer
diagnostic code before the eligibility
period (n=5517)
- Metastases present at diagnosis or
within the first 6 months after diagnosis
(n=397)
- No date of diagnosis (n=17)
- Date of 1st tamoxifen/aromatase
inhibitors prescription more than 3
months before breast cancer diagnosis
(n=516)
- Date of 1st tamoxifen/aromatase
inhibitors prescription more than a year
after diagnosis (n=328)
- Concurrent use of tamoxifen and
aromatase inhibitors (n=17)
Women with breast cancer who received
at least one prescription of tamoxifen /
aromatase inhibitors after 1 January 1998
(n=13479)
Women on tamoxifen
n=10806
Women on aromatase inhibitors
n=2673
Women under 40 years
 at diagnosis on 
tamoxifen
(Tam 40)
n=416
Women over 50 years
diagnosed before 2000
on tamoxifen
(Tam 50)
n=1435
Women over 50 years
diagnosed after 2006 on
aromatase inhibitors
(AI 50)
n=1562
Figure 1 Study flow chart.
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stime data on AI compliance in a large commercial database. The
mean compliance with anastrozole ranged from 82 to 88% in the
first 12 months of treatment, and from 62 to 79% in the third year.
Our results, taking into account that Partridge et al (2008) were
focusing on prescription claims, whereas we are studying the
prescription issued by the physician, are consistent.
However, our results comparing tamoxifen to AI use in older
women contrast with these from the only comparative study
available to date (Ziller et al, 2009). This German retrospective
study on women initiating a treatment in 2004–2005 reported, in a
small sample of women (n¼89), a lower compliance with
anastrozole (80 vs 69%). In the study time period, anastrozole
was not a standard treatment according to the German treatment
guidelines, although already largely prescribed. In this study,
women who received anastrozole were older (65 years old on
average for tamoxifen vs 72 for anastrozole) and had different
tumour characteristics as compared with those receiving
tamoxifen (e.g., 20% of in situ tumours for tamoxifen as compared
with 3% for anastrozole) (i.e., indication bias). The different
characteristics of women in the two groups may translate into
different compliance rates. Oldest age group has been showed to be
associated with lower compliance rates (Partridge et al, 2003;
Barron et al, 2007; Kahn et al, 2007; Owusu et al, 2008). As
tamoxifen is nowadays considered a less efficient adjuvant therapy
to lower the risk of BC recurrence, it is in most cases only
prescribed owing to personal characteristics of the patient
(indication bias). To avoid this bias, compliance with AIs should
be compared to compliance with tamoxifen when tamoxifen was
the only therapeutic option. This is the reason why we used an
historical cohort for the tamoxifen reference group when this latter
treatment was the reference treatment.
Negative beliefs about treatment are known to decrease
compliance in numerous diseases (Horne and Weinman, 1999).
A similar association was found for tamoxifen in BC (Fink et al,
2004; Lash et al, 2006). Little is known on patients’ beliefs on AIs.
However, as physicians were prompt to adopt AIs in replacement
of tamoxifen even before publications of guidelines (Buzdar and
Macahilig, 2005; Chlebowski, 2008), one can speculate that
physicians were confident in the efficacy of a newer treatment
and conveyed this message to patients. This may be a possible
explanation for the lower rates of treatment discontinuation
among women on AI, observed in our study. We need further
studies and data to support this hypothesis. An alternative or
complementary explanation may be a better treatment tolerance in
the AI group as compared with tamoxifen as previously reported in
the ATAC trial (Buzdar et al, 2006).
Previous observational studies on Tam have identified younger
age as a factor associated with lower compliance (Partridge et al,
2003; Barron et al, 2007; Kahn et al, 2007; Hershman et al, 2010).
One of these studies focused on self-report of compliance, likely to
Table 1 Characteristics of study population
Characteristics Tamoxifen AIs
Tamoxifen in women
under 40 years
Tamoxifen in women
over 50 years diagnosed
before 2000
AIs in women
diagnosed after 2006
Number of patients 10806 2673 416 1435 1562
Mean age at cohort entry (s.d.) 62.0 (14.0) 70.8 (12.4) 35.9 (3.3) 67.4 (12.0) 69.7 (12.0)
Mean follow-up in years (s.d.) 2.7 (1.8) 1.6 (1.3) 2.8 (1.7) 3.5 (1.8) 1.0 (0.7)
Switch between treatments (%) 2827 (26.2) 374 (14.0) 45 (10.8) 194 (13.5) 150 (9.6)
BC recurrence/or contralateral BC (%) 547 (5.1) 117 (4.4) 66 (15.9) 114 (7.9) 27 (1.7)
Death (%) 652 (6.0) 276 (10.3) 8 (1.9) 165 (11.5) 77 (4.9)
Thrombo-embolic event (%) 370 (3.42) 84 (3.14) 4 (0.9) 91 (6.3) 32 (2.1)
Endometrial cancer (%) 20 (0.19) 3 (0.11) 1 (0.24) 2 (0.14) 1 (0.06)
NSAIDs or ASA use 3443 (31.9) 1090 (40.8) 88 (21.2) 489 (34.1) 590 (37.8)
Abbreviations: AIs¼aromatase inhibitors; ASA¼acetylsalicylic acid; BC¼breast cancer; NSAIDs¼non-steroidal anti-inflammatory drugs; s.d.¼standard deviation.
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sprovide overestimates of compliance (Kahn et al, 2007). The three
other studies reported prescription refill rates as estimates of
compliance rates; however, they used either commercial database
(Hershman et al, 2010) or databases comprising mostly socially
disadvantaged women (Partridge et al, 2003; Barron et al, 2007).
However, in the subgroup of younger patients, no specific
description of the rates of compliance and patterns of treatment
discontinuation has been provided. The rapid decrease in use of
tamoxifen that we observed is of particular concern in this
subgroup of women. They present poorer outcomes of BC as
compared with older women (Adami et al, 1986; Chung et al, 1996;
Gnerlich et al, 2009). There is no alternative recommended
hormonal treatment available and as it has been established that
a 1- or 2-year treatment is less effective than a full 5-year course
(1998). The high rates of non-persistence contrast with the study of
Thewes et al (2005) reporting, using patient preference interviews,
that modest gains in survival were sufficient for women under 40
with BC to find worthwhile a 5-year tamoxifen treatment. The
reasons for early treatment discontinuation are largely unknown in
younger women. However, several specificity of this subgroup may
have a role in the difference of compliance observed. Younger
women face specific consequences of systemic treatment including
menopausal symptoms, sexual dysfunction, and fertility issues
(Fallowfield et al, 1999; Pellegrini et al, 2009), and they also suffer
from higher psychosocial distress and lower quality of life after BC
as compared with older women (Mor et al, 1994; Ganz et al, 2003).
Our study has several strengths. First, it is population based as
opposed to studies using commercial health programme databases.
These latter sources of data provide results that may be system-
atically biased because of the exclusion of different subgroups of
the general population depending on the programme eligibility.
Access to medical care and cost of treatment is likely to impact
compliance. In the UK, National Health Services provide universal
coverage. During the time period of the study, treatments were
dispensed with a fixed prescription charge per item. Exemption of
prescription charges are based on patient characteristics (e.g., over
60 years of age). Use of treatment is measured in our study with no
differential cost issues between tamoxifen and AIs. The difference
observed between the two treatments is therefore independent of
cost issues. Second, the validity of the information recorded in our
source of data, the GPRD, has been largely studied and shown to be
high. In terms of the recorded information on drug exposures and
diagnoses, the GPRD has been validated (Lawrenson et al, 1999,
2000; Jick et al, 2003). More specifically, this database provides BC
incidence closely similar to that of the national registration data
(Kaye et al, 2000). Third, the size of the database enabled the
selection of large samples even for our smaller group, BC in
younger women. Fourth, we are studying prescriptions written by
physicians, an objective measure of exposure, free of recall bias
because of the prospective nature of data collection in the GPRD.
A limitation of our study is that we do not have access to exact
data on patient compliance. Prescriptions written by physician
overestimate what patients actually ingest. However, although
methodologies to evaluate compliance are numerous, they all have
advantages and disadvantages and none is considered as a gold
standard (Osterberg and Blaschke, 2005). Rate of prescription
refills is an objective measure and has been shown in countries
with universal health coverage to provide accurate measures of
overall compliance (Lau et al, 1997). We use a proxy measure of
prescription refills as we have access to prescription issued by the
GP. Moreover, the clinical significance of our results is not
modified by the fact that we underestimate treatment discontinua-
tion rates. At least half of women stop their treatment prematurely,
a proportion large enough to stress the need for intervention to
improve compliance with and maintenance of treatment. Third,
while tamoxifen and AI use may be overestimated, this over-
estimation affects both groups similarly and therefore the
magnitude of the difference between younger and older women
and between tamoxifen and AI is not likely to be modified.
To our knowledge, our study is the first large observational
study to report comparative data on the use of AIs as compared to
tamoxifen and to provide detailed information on real-life use of
tamoxifen in younger women.
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